Mustang Bio terminates UCLA license for PSCA CAR T program, ends MB-105 development

MUSTANG BIO, INC.

Terminated UCLA License Agreement for PSCA CAR T technology, effective ~Aug 9, 2023.
No early termination penalties incurred.
Previously terminated PSCA Technology License with City of Hope on May 17, 2023.
Licensed technology targeted prostate cancer, pancreatic cancer, and other solid tumors.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MUSTANG BIO, INC. terminated UCLA License Agreement with Regents of the University of California (effective 2023-07-10).

Action: termination
Agreement: license
Counterparty: Regents of the University of California
Effective: 2023-07-10

Exact text from the filing

on July 10, 2023, the Company terminated the Exclusive License Agreement, dated as of March 17, 2017, by and between the Company and the Regents of the University of California (the “UCLA License Agreement”).

View on SEC.gov

Browse all material agreements →

MUSTANG BIO, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-079819

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.